Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
In Vitro Enzymatic Inhibitory Activity Assay from US Patent US20240132489: "AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF"
Assay data:55 Active, 55 Activity ≤ 1 µM, 55 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Activity Inhibition Assay on CDK Family Kinases from US Patent US20240109898: "SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE DERIVATIVES, COMPOSITIONS AND PHARMACEUTICAL USES THEREOF"
Assay data:84 Active, 83 Activity ≤ 1 µM, 84 Tested
CDK2/Cyclin E1 Full Length ADP-Glo Kinase Assay from US Patent US20240092761: "QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:111 Active, 104 Activity ≤ 1 µM, 122 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
CDK1/Cyclin B1 ADP-Glo Kinase Assay from US Patent US20240092761: "QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:83 Active, 59 Activity ≤ 1 µM, 122 Tested
CDK2/Cyclin E1 HTRF Enzyme Activity Assay from US Patent US11919904: "Sulfonylamide compounds as CDK2 inhibitors"
Assay data:14 Active, 14 Activity ≤ 1 µM, 14 Tested
CDK2/Cyclin E1 Full length ADP-Glo Kinase Assay from US Patent US20240034731: "AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:95 Active, 92 Activity ≤ 1 µM, 97 Tested
CDK1/Cyclin B1 ADP-Glo Kinase Assay from US Patent US20240034731: "AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:75 Active, 1 Activity ≤ 1 nM, 52 Activity ≤ 1 µM, 99 Tested
Assay for Inhibition of CDK2/CyclinE1 from US Patent US20240033264: "CDK INHIBITORS"
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
CDK2 SGC Tm panel (DSF)
Assay data:1 Tested
SummaryRelated BioAssays by Target
CDK2/CYCLINA Invitrogen Lab (UK) kinase screen (BI)
Inhibition of CDK2/cyclin A (unknown origin) at 10 uM by biochemical hotspot kinase assay
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of CDK1/cyclin E (unknown origin) at 10 uM by biochemical hotspot kinase assay
Inhibition of CDK1/cyclin B (unknown origin) at 10 uM by biochemical hotspot kinase assay
Inhibition of GST-tagged human CDK2/Cyclin A2 expressed in baculovirus infected Sf9 cells using 5-FAM-QSPKKG-CONH2 as substrate at 10 uM incubated for 60 mins in presence of ATP relative to control
Inhibition of C-terminal His6 tagged human full length CDK1/N-terminal GST-tagged human full length Cyclin B expressed in baculovirus infected Sf21 cells using 5-FAM-QSPKKG-CONH2 as substrate at 10 uM incubated for 60 mins in presence of ATP relative to control
Inhibition of C-terminal His6 tagged human full length CDK1/N-terminal GST-tagged human full length Cyclin B expressed in baculovirus infected Sf21 cells using 5-FAM-QSPKKG-CONH2 as substrate incubated for 60 mins in presence of ATP
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on